mixed-results-for-delistings-in-singapore

Mixed results for delistings in Singapore

Templeton questions MBKÆs offer to buy out minority shareholders in AsiaPharm, while TecityÆs plan to delist Straits Trading gets a fillip as the competing bidder withdraws.
Delisting hopefuls in Singapore have achieved mixed results this week with MBK hitting a hurdle in its $252 million plan to delist AsiaPharm, and Tecity moving a step forward in its $1.5 billion bid for Straits Trading.

The bid by private equity firm MBK Partners for AsiaPharm was in focus yesterday when Templeton Asset Management president Mark Mobius said the fund was ônot convinced by the offerö. Mobius says the offer price ôseverely undervalues AsiaPharm and is highly disadvantageous to minority shareholdersö. He also claims that full disclosure about the agreement between MBK and AsiaPharm's directors has not been provided to minority shareholders.

Templeton was responding to a tender offer announced...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222